<DOC>
	<DOCNO>NCT00744497</DOCNO>
	<brief_summary>The purpose study determine whether survival prolong patient castration-resistant prostate cancer receive dasatinib docetaxel prednisone .</brief_summary>
	<brief_title>Randomized Study Comparing Docetaxel Plus Dasatinib Docetaxel Plus Placebo Castration-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>History histologically diagnose prostate cancer Evidence metastatic disease 1 following : compute tomography scan , magnetic resonance imaging , bone scan , skeletal survey Evidence progression , define 1 following : rise prostate specific antigen level least 1 week apart final value &gt; =2 ng/mL ; progression measurable nodal visceral disease , nodal lesion &gt; =20 mm visceral lesion measurable per response evaluation criterion solid tumor ( Response Evaluation Solid Tumors , version 1 ) ; 2 lesion appear bone scan compare previous scan ; local recurrence prostate prostate bed Maintaining castrate status : Participants undergone surgical orchiectomy receive continue medical therapy , gonadotropin release hormone analog , maintain castrate level serum testosterone &lt; =50 ng/dL Eastern Cooperative Oncology Group Performance Status 0 2 At least 4 week since investigational agent prior start study therapy At least 8 week since radioisotope therapy prior start study therapy Recovery local therapy include surgery radiation/radiotherapy minimum 7 day prior start study therapy Required initial laboratory value : white blood cell count &gt; =3,000/mm^3 ; absolute neutrophil count &gt; =1,500/mm^3 ; platelet count &gt; =100,000/mm^3 ; creatinine level &lt; =1.5*upper limit normal ( ULN ) ; bilirubin &lt; =ULN ; aspartate aminotransferase &lt; =2.5*ULN ; alanine aminotransferase &lt; =2.5*ULN . Symptomatic brain metastasis leptomeningeal metastasis Clinically significant cardiovascular disease , include myocardial infarction ; ventricular tachyarrhythmia within 6 month ; prolong QTc &gt; 450 msec ; ejection fraction &lt; 40 % ; major conduction abnormality , unless cardiac pacemaker present Pleural pericardial effusion Common Terminology Criteria ( CTC ) grade Peripheral neuropathy CTC Grade &gt; =2 Currently active second malignancy nonmelanoma skin cancer . Participants consider currently active malignancy complete therapy consider ( physician ) less 30 % risk relapse Uncontrolled intercurrent illness include ongoing active infection , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement HIV infectionpositive patient receive combination antiretroviral therapy History allergic reaction attribute compound similar chemical biologic composition investigational agent Receipt investigational agent treatment prostate cancer Prior cytotoxic chemotherapy metastatic setting , exception estramustine Patients may continue daily multivitamin must discontinue herbal , alternative , food supplement enrollment Ketoconazole must discontinue 4 week prior start study therapy Antiandrogens must discontinue prior start study therapy . Patients history response antiandrogen subsequent progression antiandrogen assess antiandrogen withdrawal response 4 week . Observation antiandrogen withdrawal response necessary never respond antiandrogens Bisphosphonates must initiate within 28 day prior start study therapy QT prolong agent strongly associate torsade de pointes .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>